1.94

8.49% -0.18

Pre-market: 1.93 -0.01 -0.52%

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $1.94, with a volume of 876.87K. It is down -8.49% in the last 24 hours and down -10.39% over the past month. Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Previous Close:

$2.12

Open:

$2.11

24h Volume:

876.87K

Relative Volume:

0.56

Market Cap:

$246.14M

Revenue:

Net Income/Loss:

$-45.44M

P/E Ratio:

-5.5429

EPS:

-0.35

Net Cash Flow:

$-42.28M

1W Performance:

+10.86%

1M Performance:

-10.39%

6M Performance:

+12.79%

1Y Performance:

+31.08%

1-Day Range:

$1.91

$2.15

1-Week Range:

$1.68

$2.19

52-Week Range:

$0.765

$4.08

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CMPX's Discussions on Twitter

Compare CMPX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMPX Compass Therapeutics Inc	1.94	246.14M	0	-45.44M	-42.28M	-0.35
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-24-25	Initiated	Guggenheim	Buy
Feb-19-25	Initiated	Piper Sandler	Overweight
Dec-23-24	Initiated	D. Boral Capital	Buy
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

Apr 27, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Apr 27, 2025

Apr 24, 2025

It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News

Apr 24, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World

Apr 24, 2025

Apr 23, 2025

What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com

Apr 23, 2025

Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com

Apr 23, 2025

Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World

Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 22, 2025

Apr 21, 2025